Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage

LIFE SCIENCES

卷:231

Review

Yaribeygi, Habib¹  Lhaf, Fadel²  Sathyapalan, Thozhukat²  Sahebkar, Amirhossein^3,4,5 

[1] Semnan Univ Med Sci, Physiol Res Ctr, Semnan, Iran

[2] Univ Hull, Hull York Med Sch, Acad Diabet Endocrinol & Metab, Kingston Upon Hull, N Humberside, England

[3] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran

[4] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran

[5] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran

关键词: SGLT2 inhibitor;    GLP-1 receptor agonist;    DPP-4 inhibitor;    Oxidative stress;    Apoptosis;    Diabetes mellitus;    Caspase;    Cancer;   

DOI  :  10.1016/j.lfs.2019.06.013

来源: Elsevier

【 摘 要 】

Apoptosis is a complicated process that involves activation of a series of intracellular signaling. Tissue injuries from diabetes mellitus mostly occur as a consequence of higher rate of apoptosis process due to activation of a series of molecular mechanisms. Several classes of anti-hyperglycaemic agents have been developed which could potentially modulate the apoptotic process resulting in fewer tissue damages. Novel types of anti-hyperglycaemic medications such as sodium glucose cotransporters-2 inhibitors, glucagon like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors have shown to provide potent anti-hyperglycaemic effects, but their influences on diabetes-induced apoptotic injuries is largely unknown. Therefore, in the current study, we reviewed the published data about the possible effects of these anti-hyperglycaemic agents on apoptosis in diabetic milieu as well as in cancer cells.

【 授权许可】

Free